Quantcast

IPS and Wuhan Pharmaceutical Industry Design Institute Partnership Announce Agreement

March 31, 2008

IPS, a leading, full-service engineering, design, construction management, validation, and compliance company dedicated to assisting pharmaceutical and biotech companies, today announced a new agreement with Wuhan Pharmaceutical Industry Design Institute (WPIDI), a leading pharmaceutical engineering design institute in China to partner and jointly pursue pharmaceutical and biotechnology projects.

With a comprehensive list of services in project design, consultation, turnkey contracting, supervision and computer application, WPIDI is able to work on a variety of jobs in the pharmaceutical, health care, fine chemicals, clean room, and civil and municipal sectors.

“IPS and WPIDI are very pleased to enter into this partnership,” says Dave Goswami, PE, President and Chief Operating Officer of IPS. “This is a strategic collaboration between two strong companies with complementary skills. Our clients will certainly benefit from our combined knowledge and experience.”

“Currently, IPS and WPIDI are partnering on the detailed design of an aseptic fill finish facility to be built in China for FDA approved products,” stated Patrick Bucklen, Principal and Senior Director, International Products, IPS. “We are both committed to designing, building and validating high performance, technically complex facilities for all of our clients on time and under budget.”

About IPS

Integrated Project Services (IPS), www.ipsdb.com, is a full-service, engineering firm servicing the pharmaceutical and biotechnology industries as well as medical device, diagnostics and specialty chemical. IPS services include technical consulting, engineering and design, design/build, construction management, commissioning, and compliance. Located in Lafayette Hill, PA, IPS has full service branch offices in Pennsylvania, North Carolina, New Jersey, California, Indiana, Puerto Rico and India.

About WPIDI

Wuhan Pharmaceutical Industry Design Institute (WPIDI) of China National Pharmaceutical Group Corp. (SINOPHARM), www.wpidi.cn, was founded in 1969 and originally under the leadership of the State Pharmaceutical Administration of China. For more than 30 years of development, WPIDI has formed a Class A national comprehensive design institute, which takes pharmaceutical design as its mainstay with a complete set of service for disciplines, the abundant technical strength, a wide range of business and the multitudinous design fields. WPIDI employees over 200 people, with 95% of those employed being various technical personnel. WPIDI has placed constant emphasis on elaborate design, hospitable service, high efficiency and fine quality, and continuous innovation, which is demonstrated by the institute’s multiple awards; including five National Fine Design Prizes and over 40 provincial and ministerial Fine Design Prizes.




comments powered by Disqus